Ernexa Therapeutics (ERNA) EBIT Margin (2016 - 2024)
Historic EBIT Margin for Ernexa Therapeutics (ERNA) over the last 14 years, with Q4 2024 value amounting to 14194.74%.
- Ernexa Therapeutics' EBIT Margin fell 24294300.0% to 14194.74% in Q4 2024 from the same period last year, while for Sep 2025 it was 52215.79%, marking a year-over-year decrease of 492408700.0%. This contributed to the annual value of 2612.33% for FY2024, which is 185226700.0% up from last year.
- According to the latest figures from Q4 2024, Ernexa Therapeutics' EBIT Margin is 14194.74%, which was down 24294300.0% from 463.86% recorded in Q3 2024.
- Ernexa Therapeutics' EBIT Margin's 5-year high stood at 99142.86% during Q2 2022, with a 5-year trough of 14194.74% in Q4 2024.
- Over the past 4 years, Ernexa Therapeutics' median EBIT Margin value was 463.86% (recorded in 2024), while the average stood at 3686.68%.
- Per our database at Business Quant, Ernexa Therapeutics' EBIT Margin tumbled by -973659000bps in 2023 and then soared by 103302600bps in 2024.
- Quarter analysis of 4 years shows Ernexa Therapeutics' EBIT Margin stood at 142.72% in 2020, then skyrocketed by 69565bps to 99142.86% in 2022, then plummeted by -112bps to 11765.31% in 2023, then dropped by -21bps to 14194.74% in 2024.
- Its EBIT Margin stands at 14194.74% for Q4 2024, versus 463.86% for Q3 2024 and 10491.49% for Q2 2024.